PMID- 22488360
OWN - NLM
STAT- MEDLINE
DCOM- 20120718
LR  - 20181201
IS  - 1521-4141 (Electronic)
IS  - 0014-2980 (Linking)
VI  - 42
IP  - 3
DP  - 2012 Mar
TI  - Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis.
PG  - 569-72
LID - 10.1002/eji.201242402 [doi]
AB  - Autoimmune diseases including multiple sclerosis (MS) are the result of an 
      imbalanced immune tolerance network. Dendritic cells (DCs) are key players in 
      both initiating immunity (immunogenic DCs) and regulating immune responses 
      (tolerogenic DCs = tolDCs) and are potential targets for the treatment of MS. 
      While the immunogenic potential of DCs in fighting infection and cancer has been 
      well established, approaches that exploit their tolerogenic features to promote 
      transplantation tolerance and autoimmunity have emerged only more recently. 
      TolDCs usually maintain antigen-specific T-cell tolerance either directly by 
      inducing anergy, apoptosis, or phenotype skewing or indirectly by induction of 
      regulatory T (Treg) cells. The use of ex vivo-generated tolDCs is an experimental 
      approach to achieve tolerance towards myelin-antigen-specific CD4(+) T cells. In 
      the article by Raiotach-Regue and colleagues (Eur. J. Immunol. 2011. 42:772-783) in 
      this issue of the European Journal of Immunology, advances in human tolDC 
      preparation and promise for autologous therapy are described. These findings 
      raise hopes of achieving the "ideal" of a highly-specific, causally-oriented 
      immune intervention for central nervous system (CNS) autoimmunity in MS. However, 
      recent experience with antigen-specific immune interventions in MS and some 
      general caveats associated with cell-based-therapies highlight the challenges for 
      clinical translation of the "immunologist's dream" of treating autoimmunity as 
      discussed in this Commentary.
CI  - Copyright (c) 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Gross, Catharina C
AU  - Gross CC
AD  - Department of Inflammatory Disorders of the Nervous System and Neurooncology, 
      Neurology Clinic, University of Munster, Munster, Germany.
FAU - Jonuleit, Helmut
AU  - Jonuleit H
FAU - Wiendl, Heinz
AU  - Wiendl H
LA  - eng
PT  - Comment
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Eur J Immunol
JT  - European journal of immunology
JID - 1273201
RN  - 0 (Myelin Basic Protein)
SB  - IM
CON - Eur J Immunol. 2012 Mar;42(3):771-82. PMID: 22488365
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Male
MH  - Multiple Sclerosis, Relapsing-Remitting/*immunology/*therapy
MH  - Myelin Basic Protein/*immunology
MH  - T-Lymphocytes/*immunology
EDAT- 2012/04/11 06:00
MHDA- 2012/07/19 06:00
CRDT- 2012/04/11 06:00
PHST- 2012/04/11 06:00 [entrez]
PHST- 2012/04/11 06:00 [pubmed]
PHST- 2012/07/19 06:00 [medline]
AID - 10.1002/eji.201242402 [doi]
PST - ppublish
SO  - Eur J Immunol. 2012 Mar;42(3):569-72. doi: 10.1002/eji.201242402.